AVANIR Pharmaceuticals Company Description
Baseball players and AVANIR Pharmaceuticals know: A sacrifice is sometimes the only way to get ahead. The drug development firm in 2007 opted to sacrifice its marketed schizophrenia drug, FazaClo, in order to advance lead candidate Zenvia in clinical trials. It sold FazaClo, which it had bought just the year before; it is using the proceeds to continue developing Zenvia as a treatment for pseudobulbar affect -- the involuntary crying or laughing experienced by some people with such neurological disorders as Lou Gehrig's disease and multiple sclerosis. Zenvia is also in late-stage trials for diabetic neuropathic pain.
View the Comprehensive Company Description for AVANIR Pharmaceuticals
The Company Description provides a historical perspective of AVANIR Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of AVANIR Pharmaceuticals's evolution in the marketplace.
